Lead sponsor
Kailera
7 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
7
Trials led
5
Active
5,339
Total enrollment
115
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
2
Phase 2
2
Phase 3
3
Trials by status
By invitation
1
Recruiting
4
Completed
2
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have DiabetesBMI ≥30Ph 3Recruiting1,800
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesBMI ≥27Ph 3Recruiting1,700
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesBMI ≥35Ph 3Recruiting1,200
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related ComorbidityBMI ≥30Ph 2Recruiting320
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have DiabetesBMI ≥35Ph 2By invitation250